Differential expression of fucosyl GM1 and a disialoganglioside with a NeuAcα2-6Ga1NAc linkage (GD1e) in various rat ascites hepatoma cells  by Iwamori, M. et al.
Volume 198, number 1 FEBS 3476 March 1986 
Differential expression of fucosyl GM1 and a 
disialoganglioside with a NeuAca24GalNAc linkage 
(GDle) in various rat ascites ~epatoma cells 
M. Iwamori, S. Sunada, E. Ishihara, M. Moki, S. Fujimoto and Y. Nagai 
Department of Biochemistry, Faculty of Medicine, University of Tokyo, 7-3-l. Hongo, Bunkyo-ku, Tokyo 173, Japan 
Received 19 November 1985; revised version received 14 January 1986 
A distinct difference in ganglioside composition among various rat ascites hepatomas and Yoshida sarcoma 
was observed on TLC-immunostaining with anti-fucosyl GM1 antibody, and chemical and enzymatic analy- 
ses. Yoshida sarcoma and ascites hepatomas, AH13, AH66F and AH66, but not he other 9 tumor cell lines 
investigated, s~cifically contained a disialogangIioside, NeuA~Z-3G~~l-3(NeuAc~2-6)GalNAc~l- 
4Gal~l~Glc~l-lceramide (GDle), whereas the 9 ascites hepatoma cells without GDle contained fucosyl 
GM 1. The differential expression of fucosyl GM1 and GDle in various tumor cell lines indicates that differ- 
ent cell lineages express distinct metabolic pathways for gangliosides, and that the gangliosides are useful 
markers for distinguishing tumor cell lines. 
Ganglia-series gunglioside (Rat ascites hepatoma) 
1. INTRODUCTION 
In our previous study [l], we found that 
gangliosides containing ganglia-~-tetraose were 
widely distributed in various rat extraneural 
tissues, being present in erythrocytes, white blood 
cells, bone marrow and testis at particularly high 
concentrations. In rat erythrocytes, GMl, fucosyl 
GM1 and GDla were the major gangliosides, and 
the high concentration of GM1 and fucosyl GM1 
was a tissue characteristic of erythrocytes among 
the various rat tissues. Although fucosyl GM1 was 
only present in rat liver in a trace amount, it 
became detectable in the liver after malignant 
transformation with chemical carcinogens [2]. 
Also, accumulation of various gangliosides con- 
taining ganglio-N-tetraose was reported in rat 
hepatomas 27 [3] and H35 [2]. Probably, all rat 
tissues have the potential to synthesize various 
ganglioside molecules belonging to the ganglio- 
series and the tissues after transformation may be 
modulated to activate the different biosynthetic 
pathways which are generally suppressed in normal 
tissues. To elucidate the mode of modification of 
ganglioside metabolism during transformation, we 
analyzed gangliosides from various rat ascites 
hepatomas and Yoshida sarcoma, and found a 
distinct difference in the expression of polar 
gangliosides among the tumor cell lines. 
2. MATERIALS AND METHODS 
GM3, GMl, GDla, GDlb and GTlb, and 
fucosyl GM1 were isolated from human brain and 
bovine thyroid, respectively, according to [4,5]. 
Anti-asialo GM1 and anti-fucosyl GM1 antisera 
were prepared by immunizing rabbits with the 
purified antigens and their antigen specificities 
confirmed as reported in [6]. Rat ascites hepatoma 
cells, AH130, AH109, AH44, AH272, AH41C, 
AHGOC, AH414, AH7974, AH66, AH6tiF, 
AH66F and AH 13, and Yoshida sarcoma cells (ap- 
prox. 1 x 10’) at a stationary growing state were 
kindly donated by Dr H. Sato, Sasaki Institute, 
Tokyo [7]. 
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2.2. ~repuration and analysis of gangliosid~from 
hepatoma and sarcoma cells 
Extraction of total lipids followed by fractiona- 
tion into neutral and acidic lipids by DEAE- 
Sephadex A-25 (acetate form) column chro- 
matography was carried out according to [5,6]. 
2.3. TLC-immunostaining of fucosyl GM on 
thin-layer plates with rabbit anti-fucosyl GMI 
antiserum 181 
A thin-layer plate (Polygram; Macherey-Nagel, 
Diiren, FRG), after development of gangliosides 
from the cells, was incubated with the blocking 
buffer [ 1% pol~inyipyrrolidone (PVP), 1% 
ovalbumin and 0.02% NaN3 in phosphate- 
buffered saline (PBS)] at 37°C for 15 min, fol- 
lowed by incubation with anti-fucosyl GM1 an- 
tiserum diluted 1:200 with dilution buffer (3% 
PVP in PBS) at 37°C for 2 h. After washing the 
plate 5 times with washing buffer (0.1 olo Tween 20 
in PBS), the plate was reacted with blocking buffer 
at 37°C for 15 min, followed by incubation with 
peroxidase-conjugated anti-rabbit IgG antiserum 
diluted 1: 1000 for 1 h at 37°C. The enzyme activi- 
ty remaining on the plate was visualized by incuba- 
tion with 0.003% Hz02 and 4-chloro-1-naphthol in 
Tris-HCl buffer (50 mM, pH 7.4) containing 
200 mM NaCl at 37°C for 15 min. 
2.4. Structural determination of gangliosides 
The structures of the gangliosides purified by 
DEAE-Sephadex and Iatrobead column chro- 
matography were determined after permethylation 
193, sialidase (Vibrio cholerae; Calbiochem, La 
Jolla, CA) and a-fucosidase (Sigma, St. Louis, 
MO) treatment [5], and immunostaining of the 
hydrolytic products with anti-asialo GM1 antibody 
on thin-layer plates. 
3. RESULTS AND DISCUSSION 
3.1. Gangliosides from various rat ascites 
hepatoma and sarcoma cells 
A thin-layer chromatogram (TLC) of gan- 
gliosides from various rat ascites hepatoma and 
Yoshida sarcoma cells is shown in fig.1. Different 
cells varied in ganglioside composition from each 
other. Although the relative concentration of GM3 
appeared to be characteristic of each cell type, a 
distinct difference in the ganglioside composition 
was observed in the occurrence of ganglioside X, 
which was present in AH66F and AH13 ascites 
hepatoma cells and Yoshida sarcoma cells, but not 
in the other hepatoma cells, even in a trace amount 
(table 1). Ganglioside X was the major ganglioside 
in AH66F (lane 11 in fig.1). 
3.2. Structure of ganglioside X 
Ganglioside X had a lower mobility than that of 
GDla and showed an elution position corre- 
sponding to that of a disialoganglioside on the 
ganglioside map [4]. V. cholerae neuraminidase 
was able to remove the sialic acid residue complete- 
ly, and the product was proved to be asialo GM1 
by comparing its mobility and reactivity with those 
of anti-asialo GM1 antibody on a thin-layer plate 
(fig.2). Permethylation analysis of the partially 
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Fig. 1. TLC of gangliosides from various rat ascites hepatoma nd sarcoma cells. Gangliosides (5-1s pg lipid-bound 
sialic acid) were developed with chloroform-methanol-0.~~0 CaCl2 (55 : 45 : 10, by vol.) and the spots located by the 
resorcinol method. 1, AH130; 2, AH109; 3, AH44; 4, AH272; 5, AH41C; 6, AH6OC; 7, AH414; 8, AH7974; 9, AH66; 
10, AH&F; 11, AH66F; 12, AH13; 13, 14, Yoshida sarcoma. 
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Table 1 A B 
Contents of fucosyl GM1 and GDle in various rat 
ascites hepatoma cells 
Cell Fucosyl GM 1 GDle 
AH130 3.41 n.d. 
AHlO9A 9.95 n.d. 
AH44 914.54 n-d. 
AH272 30.11 n.d. 
AH4lC 18.24 n.d. 
AH6OC 74.73 n.d. 
AH414 11.87 n.d. 
AH7974 12.49 n.d. 
AH66 n.d. 458.90 
AH66cuF 45.81 n.d. 
AH66F n.d. 867.94 
AH13 n.d. 67.95 
Yoshida sarcoma n.d. 365.85 
Fucosyl GM1 and GDle were determined 
densitometrjcaliy after locating the spots with anti- 
fucosyl GM1 antiserum and resorcinol reagent, 
respectively. Detection limits of TLC-immunostaining 
(fucosyl GMI) and resorcinal reaction (GDle) were 1 
=I) w 
t 
w 
I) 
- _c - -- 
ah* 1 2 G.k 1 2 
Fig.2. TLC-immunostaining with anti-asialo GM1 
antibody {A) and orcinol staining (B) of the hydrolytic 
products of fucosyl GM1 (1) and gan~ioside X (2) from 
rat ascites hepatoma ceils. For TLC-immunostaining, 
about 10 ng fucosyl GM1 and ganglioside X were 
hydrolyzed with formic acid and neuraminidase, 
respectively. GAI, asialo GM1 . 
and 100 ng, respectively. n.d., not detected 
A 
met~ylated aldohexitol acetates showed the 
presence of 1,4,~-tri-O-acetyi-2,3,6-tri-~-methyl 
glucitol, 1,4,5-tri-0-acetyl-2,3,6-tri-O-methyl ga- 
lactitol, 1,3,5-tri-0-acetyl-2,4,6-tri-O-methyl ga- 
lactitol and 1,3,5,6-tetra-0-acetyl-2-deoxy-2-N- 
methyla~etamido-4-mono-O-methyl galactitol in 
equimolar amounts (fig.3). N-Acetylneuraminic 
acid was the sole sialic acid. Thus, the struc- 
ture of ganglioside X was concluded to be 
NeuAccu2 - 3Gal,f31- 3(NeuAm2 - 6)GalNAc,&l- 
4Gal.&l-4Glq3l-lceramide (GDle), which is 
1 identical with \ that \ of the/ compound 1 reported 
for AH7974F by Taki et al. [lo]. f 
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3.3. TLC-immunostaining of gangliosides from 
various rat ascites hepatoma and sarcoma 
cells with anti-fu~osy~ GM1 a~t~se~rn 
The antibody titer of anti-fucosyl GM1 an- 
tiserum on ELISA was 1: 20480, and the antibody 
reacted with fucosyl GM1 to a great extent but on- 
ly slightly with fucosyl asialo GMl, and not at all 
with GM3, GD3, GMl, GDla, GDlb, GTlb or 
asialo GM1 on TLC-immunostaining. More than 
5 ng fucosyl GM1 was detectable by this pro- 
RETENTION TlME(rn~n) 
Fig.3. GLC of the partially methylated aldohexitol 
acetates from gangiioside X, A, 2010 OV-275; B, 1% 
OV-17. Peaks l-4: 1,3,5-tri-O-acetyl-2,4,6-tri-O-methyl 
galactitol; 1,4,5-tri-O-acetyl-2,3,6-tri-O-methyl ga- 
lactitol; 1,4,5-tri-0-acetyl-2,3,6-tri-O-methyl glucitol; 
1,3,5, ~tetra-O-acetyl-2-deoxy-2-~-methylacet~ido~- 
mono-O-methyl galactitol, respectively. Each peak was 
identified by comparing the retention times and mass 
spectra. 
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Fig.4. TLC-immunostaining of gangliosides from various rat ascites hepatoma and sarcoma cells with anti-fucosyl GM 1 
antibody. Numbers as in fig. 1. 
cedure, As shown in figA, antigen detectable with 
anti-fucosyl GM1 antibody was present in rat 
ascites hepatoma cells, AH130, AH109, AH44, 
AH272, AH4lC, AH6OC, AH414, AH7974 and 
AH6CicuF, but not in rat ascites hepatoma ceils, 
AH66, AH66F and AH13, or Yoshida sarcoma 
cells, even in a trace amount (table 1). After isola- 
tion by DEAE-Sephadex and Iatrobead column 
chromatography, the structure of the antigen was 
determined by the same procedure as described 
above, and it was concluded to be fucosyl GM1 
from the following evidence: (i) permethylation 
analysis of the partially methylated aldohexitol 
acetates showed 1,4,5-tri-0-acetyl-2,3,6-tri-O- 
methyl glucitol, 1,2,5-tri-O-acetyl-3,4,6-tri-Q- 
methyl galactitol, 1,3,4&i-tetra-0-acetyl-2,6-di-O- 
methyl galactitol, I ,5-di-O-acetyl-2,3,4-tri-O- 
methyl fucitol and 1,3,5-tri-0-acetyi-2-deoxy-2- 
~-methylacetamido-4,6-di-O-methyl galactitol in 
equimolar amounts; (ii) the product obtained on 
formic acid treatment was identical to asialo GM1 
(fig-l) on TLC-immunostaining; and {iii) cy- 
fucosidase treatment yielded GMl. Thus, fucosyl 
GM1 and GDIe were found to be differentially ex- 
pressed among different cell lines of rat ascites 
hepatoma cells. This indicates strongly that these 
cells may be classified into two groups by utilizing 
the above two gangliosides as markers. Cells hav- 
ing fucosyl GM1 should express the synthetic 
pathway for the ganglioside via the fucosylation of 
GMl, and the other cells without fucosyl GM1 
might preferentially express the pathway through 
sialylation at the 6-position of GalNAc in GMlb 
since GMlb has been detected as the only 
monosialog~~ioside precursor in AH66F 
(Sunada et al., unpublished~. RecentIy the atten- 
tion of many investigators has been drawn to the 
metabolic modulation or regulation of glycolipids 
through induction or activation of glycosyl 
transferases during cellular differentiation, 
transformation [l l-131 and genomic DNA seg- 
ment transfection [14]; accordingly, the two cell 
lineages mentioned here should be useful for 
understanding the mechanism of the metabolic 
change of the ganglio-series gangliosides. The 
detailed ganglioside compositions of the above 
cells will be reported elsewhere. 
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